Research using animal model systems has been instrumental in delivering improved
therapies for breast cancer, as well as in generating new insights into the mechanisms that …

Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes
and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway …

The immunohistochemical (IHC) staining of the human epidermal growth factor receptor 2
(HER2) biomarker is widely practiced in breast tissue analysis, preclinical studies, and …

The oncogenic role ERBB2 amplification is well established in breast and gastric cancers.
This has led to the development of a well‐known portfolio of monoclonal antibodies and …

Simple Summary Cancer is a complex illness marked by aberrant cellular behaviors and
genetic variances, resulting in tumor heterogeneity that presents challenges in cancer …

Background Patients with metastatic HER2/neu-positive (HER2/neu+) breast cancer (BC)
often experience treatment resistance, disease recurrences and metastases. Thus, new …

Purpose Targeted therapies have resulted in major advances in the treatment of HER2-
positive breast cancers. Despite this, up to 70% of patients will develop resistance to …

Protein arginine methyltransferases (PRMT) are generally not mutated in diseased states,
but they are overexpressed in a number of cancers, including breast cancer. To address the …

Abstract Human c-ErbB2 (HER2) has long been used as a marker of breast cancer (BC) for
sub-categorization for the prediction of prognosis, and determination of therapeutic …

Angiosarcomas are a rare group of tumours which have poor prognosis and limited
treatment options. The development of new therapies has been hampered by a lack of good …